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ABSTRACT
Objective To analyse the role of multibiomarker
disease activity (MBDA) score in predicting disease
relapses in patients with rheumatoid arthritis (RA) in
sustained remission who tapered disease modifying
antirheumatic drug (DMARD) therapy in RETRO, a
prospective randomised controlled trial.
Methods MBDA scores (scale 1–100) were determined
based on 12 inflammation markers in baseline serum
samples from 94 patients of the RETRO study. MBDA
scores were compared between patients relapsing or
remaining in remission when tapering DMARDs.
Demographic and disease-specific parameters were
included in multivariate logistic regression analysis for
defining predictors of relapse.
Results Moderate-to-high MBDA scores were found in
33% of patients with RA overall. Twice as many patients
who relapsed (58%) had moderate/high MBDA compared
with patients who remained in remission (21%). Baseline
MBDA scores were significantly higher in patients with RA
who were relapsing than those remaining in stable
remission (N=94; p=0.0001) and those tapering/stopping
(N=59; p=0.0001). Multivariate regression analysis
identified MBDA scores as independent predictor for
relapses in addition to anticitrullinated protein antibody
(ACPA) status. Relapse rates were low (13%) in patients
who were MBDA−/ACPA−, moderate in patients who were
MBDA+/ACPA− (33.3%) and MBDA−ACPA+ (31.8%)
and high in patients who were MBDA+/ACPA+ (76.4%).
Conclusions MBDA improved the prediction of relapses
in patients with RA in stable remission undergoing DMARD
tapering. If combined with ACPA testing, MBDA allowed
prediction of relapse in more than 80% of the patients.
Trial registration number EudraCT 2009-015740-42.
INTRODUCTION
Reaching a state of disease remission in rheumatoid
arthritis (RA) is considered as the primary treat-
ment goal in RA.1 2 Due to earlier diagnosis, more
efficient use of disease modifying antirheumatic
drugs (DMARDs) and a broader drug
armamentarium, an increasing number of patients
with RA experience disease remission. For instance,
data from the Norvegian-DMARD study show
doubling of remission rates in the last decade.3
Moreover, many patients maintain their remission
state over two subsequent visits.4 Hence, strategies
to manage patients with RA in remission, including
the possibility to taper or even stop treatment, gain
growing importance.5–8 Especially, predictive
markers are needed for identifying patients, in
which treatment can be successfully tapered
without facing a high risk for relapse of RA.
We have recently conducted a randomised pro-
spective study in patients with RA in remission.10 In
this RETRO study, we aimed to define the likelihood
for disease recurrence in patients with RA when
tapering and/or stopping DMARD treatment. While
recurrence of disease was higher in patients tapering
or stopping DMARDs than in those remaining on
treatment, it was stunning that more than half of the
patients still kept their remission state despite taper-
ing the DMARDs. These data suggested that tapering
or stopping antirheumatic drugs may be a feasible
option in a subset of patients with RA, raising the
question on the respective patient profile, which is
able to taper or stop DMARD treatment.
Presence of anticitrullinated protein antibodies
(ACPA) has shown to increase the likelihood for
relapse of disease when tapering DMARDs.10 Still,
prediction models for disease relapse based on
ACPA need further improvement. A more compre-
hensive assessment of inflammation, which (a)
allows detection of residual subclinical inflamma-
tion and (b) extends beyond mere detection of
acute phase responses, may help to improve predic-
tion of disease relapse. Notably, absence of clinical
joint swelling does not necessarily mean true
absence of inflammation. In accordance, imaging of
joints of patients with RA in remission revealed a
rather high prevalence of inflammatory lesions
despite absence of respective clinical changes.11–13
While the meaning of subclinical inflammation is
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still under debate, these findings indicate that local inflammatory
changes are still present in patients with RA in remission and
may precipitate disease relapses.
To address this concept, we performed a comprehensive
assessment of inflammation by a multibiomarker disease activity
(MBDA) test in the serum of patients with RA who were in sus-
tained remission and were included into the prospective
RETRO study undergoing DMARD tapering. We hypothesised
that patients with higher levels of inflammation markers may
face an increased risk for relapses in comparison with those
showing overall low markers of inflammation.
METHODS
Patients and inclusion criteria
RETRO is phase-3, multicentre, randomised, open, prospective,
controlled, parallel-group study (EudraCT number
2009-015740-42). Details of the study are described elsewhere.10
The primary objective of the study is to evaluate the possibility of
tapering or stopping DMARDs in patients fulfilling the American
College of Rheumatology (ACR)/European League Against
Rheumatism (EULAR) 2010 classification criteria for RA.14 To be
enrolled, patients had to have RA for at least 12 months and sus-
tained clinical remission with a disease activity score (DAS)-28
based on erythrocyte sedimentation rate (ESR) of less than 2.6 for
at least 6 months.15 16 In addition, patients had to receive stable
treatment with conventional and/or biological DMARDs without
alteration in dose for at least 6 months. The study was approved by
the ethic committee of the Friedrich-Alexander-University of
Erlangen-Nuremberg, all local ethical committees of the external
centres as well as the Paul Ehrlich Institute (PEI) and was conducted
according to the ethical principles of the Declaration of Helsinki.
Treatment and follow-up
Patients were randomised into three different trial arms: Arm 1
(continuation) kept existing conventional and/or biological
DMARD regimen at full dose for 12 months. Arm 2 (tapering)
reduced the dose of all conventional and/or biological
DMARDs by 50%. Arm 3 (stop) reduced the dose of all conven-
tional and/or biological DMARDs by 50% for the first 6 months
before entirely stopping all DMARDs. Details on the mode of
tapering DMARDs are outlined elsewhere.10 Primary efficacy
parameter was disease activity, which was assessed at baseline
and after months 3, 6, 9 and 12 using the DAS28-ESR. Relapse
of disease was defined as leaving DAS28 remission correspond-
ing to a DAS28-ESR score of >2.6.
Assessment of demographic and disease-specific
parameters
Age, sex and body mass indices were recorded in all patients.
With respect to disease-specific parameters, disease duration,
remission duration, tender joint count 68, swollen joint count
66, visual analogue scales (VAS) for pain and patient global were
assessed. In addition, C reactive protein (CRP) level, ESR and
the presence of rheumatoid factor (RF) as well as ACPA were
measured. Composite scores including DAS28-ESR, DAS28-CRP,
ACR/EULAR Boolean remission16 and Health Assessment
Questionnaire (HAQ-DI) were calculated at baseline and each
follow-up visit, Antirheumatic therapy and any other concomi-
tant treatment were recorded at baseline and at follow-up visits.
Serum analyses
Baseline serum was available from 94 of the first 101 patients of
the RETRO study. Twelve inflammation markers were measured
in the baseline serum samples of all these 94 patients using the
MBDA blood test, which is commercially available in the USA
(Vectra DA, Crescendo Bioscience, Myriad Genetics, Salt Lake
City, Utah, USA). In developing the MBDA test, these markers
were selected from 130 candidates in prior studies by a combin-
ation of objective regression modelling and assay performance
criteria.17 18 Serum was stored at –80°C before the analysis. All
analyses were performed in blinded fashion by the central labora-
tory of Crescendo Bioscience (South San Francisco, California,
USA). The 12 inflammation markers included epidermal growth
factor (EGF), vascular endothelial growth factor A (VEGF-A),
interleukin 6 (IL-6), serum amyloid A (SAA), CRP, vascular cell
adhesion molecule 1 (VCAM-1), matrix metalloproteinase 1
(MMP-1), matrix metalloproteinase 3 (MMP-3), tumour necrosis
factor receptor 1 (TNF-RI), human cartilage glycoprotein 39
(YKL-40), leptin and resistin. Measurement of serum concentra-
tions was done by immunoassays using three custom multiplex
panels on the Meso Scale Discovery Sector Imager 6000: panels
A (for EGF, IL-6, leptin, and VEGF-A), B (for CRP, SSA, and
VCAM-1) and C (for MMP-1, MMP-3, resistin, TNF-RI, and
YKL-40). Concentrations were calculated using standard curves
using four-parameter logistic regression curve fits.18
Calculation of MBDA scores
The algorithm for calculating MBDA scores based on the serum
levels of the aforementioned 12 serum proteins has been validated
and described previously.16 17 The algorithm was the same as those
used in the previously developed and validated MBDA test, Vectra
DA (Crescendo Bioscience). Briefly, this algorithm used serum bio-
marker concentrations to separately estimate TJC28, SJC28 and
VAS-GH. The estimates for TJC28, SJC28 and VAS-GH were com-
bined with a CRP test result to calculate an overall MBDA score: a
whole number on a scale of 1–100, using a validated formula
analogous to that of the DAS28-CRP.16 The algorithm was previ-
ously developed and trained using independent serum samples
from different studies.18–20 The categories for MBDA scores are
less than 30 units for low disease activity, 30–44 units for moderate
and more than 44 units for high disease activity.17
Statistical analysis
In descriptive analyses treatment, arms were analysed for demo-
graphical and disease-related parameters. Descriptive results are
stated in medians and interquartile ranges due to deviation from
normal distribution. Corresponding inferential comparisons of
subgroups were calculated using Kruskal–Wallis or Mann–
Whitney U-tests for numerical variables and exact χ2-tests for
nominal characteristics. A multivariate logistic regression model
using ‘enter’ method was used to predict the occurrence of
disease relapses from the following set of baseline characteristics
including an intercept term: age, sex, duration of disease, dur-
ation of remission, RF status, ACPA status, ACR/EULAR remis-
sion status, randomisation arm (treatment continuation was
designated the reference category), biological DMARDs use and
MBDA score. Kaplan–Meier plots were used to illustrate
relapses over the 12 months of the study with respect to (a) low
versus moderate-to-high MBDA scores and (b) ACPA positivity.
SPSS software V.21 was used for calculations. p Values ≤0.05
were considered statistically significant.
RESULTS
Baseline characteristics of the patients
Baseline characteristics of the 94 RETRO patients analysed are
described in table 1. Briefly, 35 of the 94 patients had been ran-
domised into arm 1 continuing full-dose DMARD treatment
over 1 year. The other 59 patients had been randomised into
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the two tapering arms, with arm 2 reducing all DMARDs by
50% for 1 year (N=32) and arm 3 stopping all DMARDs after
a 6 months tapering interval (N=27). Patients had established
RA and were in sustained remission with a median duration of
remission of 12 months. More than two-thirds of the patients
were also fulfilling the ACR/EULAR remission criteria. Levels
for CRP (median: 0.28 mg/L) and ESR (median: 13 mm) were
normal and like MBDA scores evenly distributed among the
three strategy arms. HAQ-DI was generally low and not signifi-
cantly different among the different treatment arms. The major-
ity of patients were receiving methotrexate (84%), while
biological DMARDs were used by 37% of the patients with
TNF inhibitors the most frequently used entity. After 1 year, 63
of the 94 patients remained in remission, whereas 31 patients
relapsed.
Distribution of MBDA scores
MBDA scores were calculated from the analysis of baseline
serum samples of 94 RETRO patients. Distribution of MBDA
scores showed that 63 patients (67%) had low MDBA scores
(<30 units), while 31 patients (33%) had moderate to high
scores (≥30 units) according to the previously established
cut-offs (figure 1A). In patients who maintained their remission
status over 1 year, MDBA scores were shifted to low scores
(79%), while moderate-to-high score were less frequent (21%)
(figure 1B). In contrast, the frequency of moderate-to-high
MBDA scores was more than twice as high (58%) in patients
subsequently experiencing a relapse (figure 1C).
MBDA scores in patients with RA relapsing and remaining in
sustained remission
We found that levels of baseline MBDA scores were significantly
(p=0.0001) higher in patients experiencing a relapse (mean
±SEM: 32.0±2.3 units) than those remaining in sustained
remission (22.6±1.2) (figure 2A). MBDA values indicating mod-
erate (30–44 units) and high (over 44 units) inflammatory
activity were clearly increased in patients experiencing a subse-
quent disease relapse (figure 2B). Subgroup analysis showed that
MBDA scores did not differ (p=0.95) between relapsing and
sustained remission patients when full-dose DMARD treatment
was continued (arm 1) (figure 1C). However, in the subgroups
of patients tapering (arm 2; p=0.0004) and stopping (arm 3;
p=0.05) DMARD treatment MBDA scores were significantly
higher in patients experiencing disease relapse. Significant
(p=0.0001) differences in baseline MBDA scores between
relapsing and sustained remission patients were also found,
when groups 2 and 3 resembling all patients tapering their
DMARD, were analysed (figure 2C). Analysis of individual com-
ponents of MBDA showed trends to higher levels of parameters
linked to acute phase response (SAA, CRP, IL-6), tissue inflam-
mation (EGF, VEGF, MMP-1 and -3) and energy metabolism
(leptin) in patients with relapse (see online supplementary figure
S1). Hence, the aforementioned significant differences in
MBDA scores between relapsing and non-relapsing patients are
not built on one single but several different serum parameters,
underscoring the strength of a composite score like MBDA.
Relation between MBDA scores and ACPA
In our previous analyses, ACPA emerged as the only predictive
factor for disease relapse in patients with RA tapering or stop-
ping their DMARD treatment.9 We therefore addressed the rela-
tion between MBDA and ACPA to test whether there is a
potential to refine the prediction of disease relapse by combin-
ing MBDA and ACPA measurements. Separate analysis of
MBDA scores in patients who were ACPA-negative (ACPA−)
and ACPA-positive (ACPA+) revealed virtually identical differ-
ences between relapsing and non-relapsing patients (figure 3A).
As previously mentioned, differences in MBDA scores between
patients relapsing and those remaining in remission were
confined to patients tapering and stopping their DMARD treat-
ment and this observation was true for both patients who were
ACPA− and ACPA+ (figure 3B). Importantly, the majority of
Table 1 Baseline characteristics of the patients
Characteristics Total population (n=94)
Continuation Tapering Stopping
p ValuesArm 1 (n=35) Arm 2 (n=32) Arm 3 (n=27)
Age, years 55.0 (19) 55.0 (19.5) 54.0 (18) 54.5 (19) 0.90
Females, % (N) 59.6 (56) 57.1 (20) 56.2 (18) 66.7 (18) 0.67
Disease duration, years 5.0 (7) 5.0 (7) 6.0 (6) 3.0 (5) 0.13
Remission duration, months 12.0 (12.0) 12.0 (27) 9.0 (12) 12.0 (10) 0.13
DAS-28, units 1.9 (0.8) 1.9 (1.1) 1.9 (0.7) 2.0 (0.9) 0.56
ACR/EULAR remission, % (N) 77.6 (73) 77.1 (27) 81.2 (26) 74.0 (20) 0.80
ESR, mm 13.0 (15) 11.0 (17) 13.0 (13) 14.5 (8.5) 0.79
CRP, mg/dL 0.28 (0.23) 0.27 (0.24) 0.28 (0.33) 0.26 (0.21) 0.57
MBDA score 21.5 (22.0) 25.0 (13.0) 19.0 (22.0) 18.0 (23.0) 0.69
HAQ, units 0.0 (0.13) 0.0 (0.13) 0.0 (0.25) 0.0 (0.16) 0.77
Positive RF, % (N) 60.6 (57) 51.4 (18) 71.8 (23) 59.2 (16) 0.23
Positive ACPA, % (N) 56.3 (53) 57.1 (20) 59.3 (19) 51.8 (14) 0.84
Methotrexate use, % (N) 84.0 (79) 85.7 (30) 71.8 (23) 96.3 (26) 0.003
Other DMARD* use, % (N) 9.5 (9) 8.5 (3) 12.5 (4) 7.4 (2) 0.78
Biological DMARD† Use, % (N) 37.2 (35) 42.8 (15) 50.0 (16) 14.8 (4) 0.014
*Leflunomide, sulfasalazine, hydroxychloroquine.
†Tumour necrosis factor inhibitors and tocilizumab; descriptive results in median (IQR) due to deviation from normal distribution, if not stated otherwise.
ACPA, anticitrullinated protein antibody; ACR, American College of Rheumatology; CRP, C reactive protein; DAS-28, disease activity score-28 (based on ESR); DMARDs, disease modifying
antirheumatic drugs; ESR, erythrocyte sedimentation rate; EULAR, European League Against Rheumatism; HAQ, health assessment questionnaire; MBDA, multibiomarker disease activity;
RF, rheumatoid factor; VAS, visual analogue scale.
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patients who were ACPA+MBDA+ were in the relapse group,
while they were extremely rare (N=3) in the sustained remission
group. Conversely, patients who were ACPA−MBDA− were
enriched in the sustained remission group, but very rarely found
in the relapse group (N=4) (figure 3C).
Based on these findings, which suggested that MBDA scores
and ACPA status independently predict the risk for relapse, we
separately calculated the relapse rates in double-negative
(ACPA−MBDA−), double-positive (ACPA+MBDA+) and single-
positive (ACPA+MBDA−:, ACPA−MBDA+) patients. While the
risk for relapse in patients with double-negative RA was very
low (13.0%), the large majority (76.4%) of double-positive
patients relapsed (χ2-test; p=0.0001) (figure 4A). Relapse
risks of single-positive patients (ACPA+MBDA−: 31.8%,
ACPA−MBDA+: 33.3%) were in between these two extremes,
indicating that MBDA scores and ACPA status independently
contribute to relapse risk in patients with RA tapering DMARD
treatment. Further evidence is provided by Kaplan–Meier curves
showing a rather rapid loss of remission status in double-positive
patients, while double-negative patients mostly remained in
remission (figure 4B). No significant differences were observed
when replacing MBDA by either CRP (p=0.15), ESR (p=0.09),
DAS28 (p=0.11), simplified disease activity index (SDAI)
(p=0.27) or clinical disease activity index (CDAI) scores
(p=0.38) (see online supplementary figure S2A–E).
Furthermore, we tested whether replacing ACPA by RF in an
MBDA based prediction model was significant. While overall
the groups showed significant differences in relapse rates
(χ2-test; p=0.001), no separation between double-negative and
single-positive groups was observed (see online supplementary
figure S2F).
Predictors for disease relapse
To further test whether MBDA scores are independent predic-
tors for relapses, we set up a multivariate logistic regression
model. In a model containing demographic variables (age, sex),
autoantibody status (ACPA, RF), randomisation arm (treatment
continuation was designated the reference category), remission
status (ACR/EULAR Boolean remission) and other disease-
specific variables (disease duration, remission duration, bio-
logical DMARD exposure), only ACPA positivity (Wald χ2=9.1,
p=0.002, OR=24.4) and MBDA score (Wald χ2=8.3,
p=0.004, OR=8.5) were identified as predictors beside the
underlying randomisation arm (Wald χ²Arm2=5.4, p=0.02,
OR=5.94; Wald χ²Arm3=4.3, p=0.04, OR=5.41) for subse-
quent relapse of disease (table 2). Overall, the model allowed
correct prediction in 81.8% of the patients.
DISCUSSION
We show that the presence of residual inflammation assessed by
a standardised panel of biomarkers is associated with a higher
relapse rate of RA when DMARDs are tapered or stopped. Our
data suggest that (a) markers of inflammation are elevated in a
subset of patients with RA in clinical remission and (b) that
these patients are at higher risk for relapse if their anti-
inflammatory treatment is reduced. Furthermore, assessment of
residual inflammatory activity allows refinement of prediction
models for relapses during DMARD tapering, if combined with
the assessment of ACPA status. Hence, more than 80% of the
relapses could be predicted when using MBDA scores in con-
junction with ACPA testing.
MBDA scores are based on the serum levels of 12 different
proteins, which provide a more comprehensive picture of
inflammation than mere assessment of CRP levels. Notably,
inflammation does not only reflect acute phase responses, but
also comprises other aspects such as local tissue inflammation,
tissue remodelling and the interphase between inflammation
and metabolism. While the MBDA score includes elements of
the acute phase response, such as CRP, IL-6 and SAA, it also
contains markers resembling local tissue inflammation (TNFRI,
EGF, VEGF-A and VCAM-1) expressed by activated synovial
fibroblasts. Furthermore, MBDA score includes MMP-1,
MMP-3 and YKL-40 indicating local tissue remodelling of the
synovium and the cartilage, whereas resistin and leptin are adi-
pokines, controlling the interaction between fat metabolism and
inflammation. Increased prevalence of disease relapses in
Figure 1 Distribution of multibiomarker disease activity (MBDA)
scores. (A) Distribution of baseline MBDA scores in patients with
rheumatoid arthritis in remission. Colours indicate low (green),
moderate (yellow) and high levels (orange). Dashed line indicates the
cut-off between low MBDA scores and moderate-to-high MBDA score.
(A) entire population; (B) patients remaining in remission and (C)
patients experiencing relapse of disease.
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patients with elevated MBDA scores may reflect subclinical
inflammation at the target tissue level such as residual synovitis
or osteitis. It is conceivable that inflammation in these patients
is effectively suppressed by DMARDs at the clinical level but
has not completely resolved. Hence, tapering of DMARDs may
permit recurrence of inflammatory disease activity associated
with clinical relapse. In contrast, patients having low MBDA
scores may indeed experience true resolution of inflammation,
which lowers the risk for disease relapse if DMARDs are
tapered. Our data suggest that MBDA scores are more effective
than clinical scores in prediction of disease relapses. As reported
previously, baseline DAS28 scores were not predictive for
relapses in the RETRO study.10 This situation may be based on
the overall very low mean DAS28 scores in our cohort, which
may hamper discrimination between patients with and without
residual inflammation by clinical instruments. It will therefore
be important to see the performance of MBDA scores in pre-
dicting relapses in other cohorts, where DMARDs were tapered
or stopped. For instance, Tanaka and colleagues have shown,
that in the specific case of TNF inhibitor withdrawal patients
with a very low DAS28 score (≤1.98 units) were more likely to
stay in low disease activity than patients with a higher baseline
DAS28 (1.98–2.6 units).21
In our previous analysis, ACPA was the only independent pre-
dictor for relapse, supporting the role of autoimmunity in the
disease course of RA. Similar findings were also reported from
other cohorts tapering or stopping DMARD treatment.22–24 In
the combined analysis of ACPA status and MDBA score, predic-
tion of relapses fundamentally improved. Hence,
double-negative patients had a very low chance for relapse
(13%), which was similar to patients remaining on full-dose
DMARD treatment. Relapse rates increased to more than 30%
in patients with either positive ACPA or elevated MBDA scores
and to more than 75% with concomitant presence of ACPA and
elevated MBDA scores. ACPA and MBDA appear to act inde-
pendently from each other in precipitating relapses, which was
Figure 2 Baseline multibiomarker disease activity (MBDA) scores in patients with relapsing and non-relapsing rheumatoid arthritis (RA). (A)
Baseline MBDA scores in patients with RA experiencing a relapse or remaining in remission (no relapse). (B) Probability plot of MBDA scores in
patients with RA experiencing a relapse or remaining in remission (no relapse). (C) MBDA scores in patients with relapsing and non-relapsing RA,
who continued treatment (study arm 1), tapered treatment (study arm 2) or stopped treatment (study arm 3). Combined results for tapering and
stopping treatment (arms 2 and 3) are shown in the last graph (from left to right). *** indicate a p value of less than 0.05 (unpaired Student’s t
test).
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supported by multiple logistic regression models. Hence, both
autoimmunity and residual inflammation appear to influence
relapse risk of RA.
In summary, we show that elevated MBDA scores inde-
pendently predict relapse of RA in the process of tapering
and stopping DMARDs. Together with the assessment of
ACPA status, MBDA score improves the prediction of
relapse risk in patients with RA, allowing defining patient
patterns with low and high relapse risks during DMARDs
tapering.
Figure 3 Influence of anticitrullinated protein antibody (ACPA) status on multibiomarker disease activity (MBDA) scores in relapsing and
non-relapsing patients. (A) Baseline MBDA scores in patients with rheumatoid arthritis experiencing a relapse or remaining in remission (no relapse)
and relation to ACPA status. (A) entire population, study arms 1–3 (left); patients tapering or stopping treatment, study arms 2 and 3 (right); (B)
patients continuing treatment, study arm 1 (left); patients tapering treatment, study arm 2 (middle) and patients stopping treatment, study arm 3
(right); (C) Distribution of MBDA scores based on relapse status, the presence of ACPA, and category of MBDA score (low(−) or moderate-to-high
(+)) p values were calculated by unpaired Student’s t test.
Figure 4 Relapse rates of rheumatoid arthritis (RA) dependent on anticitrullinated protein antibody (ACPA) and multibiomarker disease activity
(MBDA) score. (A) Risk chart for cumulative disease relapse over 1 year dependent on ACPA status and MBDA score. (−) indicates no ACPA or a low
MBDA score (<30). (+) indicates presence of ACPA or moderate-to-high MBDA score (≥30). Values indicate the incidence of relapse over 1 year for
that patient group. (B) Kaplan–Meier curves indicate loss of remission over 12 months in patients with RA in relation to ACPA status and MBDA
score: (blue) ACPA/MBDA double-negative, (green) ACPA+/MBDA−, (yellow) ACPA−/MBDA+ and (purple) ACPA/MBDA double positive. Y-axis
indicates the percentage of patients with RA in sustained remission (100% at baseline). X-axis indicates time.
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